ABSTRACT
Inactivating mutations of Foxp3, the master regulator of regulatory T cell development and function, lead to immune dysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) syndrome in mice and humans. IPEX is a fatal autoimmune disease, with allogeneic stem cell transplant being the only available therapy. In this study, we report that a single dose of adeno-associated virus (AAV)-IL-27 to young mice with naturally occurring Foxp3 mutation (Scurfy mice) substantially ameliorates clinical symptoms, including growth retardation and early fatality. Correspondingly, AAV-IL-27 gene therapy significantly prevented naive T cell activation, as manifested by downregulation of CD62L and upregulation of CD44, and immunopathology typical of IPEX. Because IL-27 is known to induce IL-10, a key effector molecule of regulatory T cells, we evaluated the contribution of IL-10 induction by crossing IL-10-null allele to Scurfy mice. Although IL-10 deficiency does not affect the survival of Scurfy mice, it largely abrogated the therapeutic effect of AAV-IL-27. Our study revealed a major role for IL-10 in AAV-IL-27 gene therapy and demonstrated that IPEX is amenable to gene therapy.
Subject(s)
Forkhead Transcription Factors , Genetic Diseases, X-Linked , Genetic Therapy , Germ-Line Mutation , Interleukin-10 , T-Lymphocytes, Regulatory , Animals , Forkhead Transcription Factors/genetics , Mice , Interleukin-10/genetics , Interleukin-10/immunology , Genetic Therapy/methods , T-Lymphocytes, Regulatory/immunology , Genetic Diseases, X-Linked/therapy , Genetic Diseases, X-Linked/immunology , Genetic Diseases, X-Linked/genetics , Interleukins/immunology , Interleukins/genetics , Diarrhea/genetics , Diarrhea/therapy , Diarrhea/immunology , Intestinal Diseases/immunology , Intestinal Diseases/genetics , Intestinal Diseases/therapy , Dependovirus/genetics , Mice, Inbred C57BL , Immune System Diseases/immunology , Immune System Diseases/therapy , Immune System Diseases/genetics , Immune System Diseases/congenital , Diabetes Mellitus, Type 1/immunology , Diabetes Mellitus, Type 1/therapy , Diabetes Mellitus, Type 1/genetics , Diabetes Mellitus, Type 1/congenital , Mice, Knockout , Lymphocyte Activation/immunology , Humans , Interleukin-27/geneticsABSTRACT
Gastric carcinoma, being one of the most prevalent types of solid tumors, has emerged as the third leading cause of death worldwide. The symptoms of gastric cancer (GC) are typically complex, which makes early detection challenging. Immune checkpoint inhibition has become the new standard targeted therapy for advanced or metastatic GC. It is currently being explored in various combinations, both with and without chemotherapy, across multiple therapies in clinical trials. Immunotherapy can stimulate immune responses in GC patients, leading to the destruction of cancer cells. Compared with traditional therapies, immunotherapy has shown strong effectiveness with tolerable toxicity levels. Hence, this innovative approach to the treatment of advanced GC has gained popularity. In this review, we have outlined the recent advancements in immunotherapy for advanced GC, including immune checkpoint inhibitors, cancer vaccines, vascular endothelial growth factor-A inhibitors, and chimeric antigen receptor T-cell therapy. Our current emphasis is on examining the immunotherapies presently employed in clinical settings, addressing the existing challenges associated with these therapeutic approaches, and exploring promising strategies to overcome their limitations.